Cdk4 Antibody (97): sc-136241

Cdk4 Antibody (97) is a mouse monoclonal IgG1 antibody engineered to detect Cyclin-dependent kinase 4 (Cdk4), also known as CDC2-like kinase 4, in mouse, rat, and human samples. Cdk4 monoclonal antibody (97) targets an epitope spanning amino acids 1-303 of the full-length recombinant rat Cdk4 protein, making anti-Cdk4 antibody (97) suitable for applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Cdk4 is a crucial serine/threonine kinase that plays a significant role in regulating the cell cycle, particularly the transition from the G1 phase to the S phase, by forming complexes with D-type cyclins. The localization of Cdk4 within the cell, primarily in the nucleus and cytoplasm, is essential for function, as Cdk4 must access and phosphorylate key substrates like the retinoblastoma protein (Rb) to drive cell cycle progression and cellular proliferation. Proper cellular distribution ensures that Cdk4 effectively controls cell growth, while mislocalization can lead to unchecked cell division, a hallmark of cancerous transformations. Additionally, Cdk4 interacts with regulatory proteins such as the inhibitor p16, which modulates activity to maintain controlled cell cycle progression and prevent tumorigenesis. The dynamic localization and interaction of Cdk4 within different cellular compartments allow for responses to various regulatory signals, ensuring accurate cell cycle regulation. By facilitating the detection of Cdk4′s location and expression levels, anti-Cdk4 antibody (97) provides researchers with essential tools to study cell cycle dynamics and implications in cancer research. Available in both non-conjugated and various conjugated forms, including horseradish peroxidase (HRP) and fluorescent tags, Cdk4 (97) antibody offers versatility to meet diverse experimental needs.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cdk4 Antibody (97) References:

1. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.  |  Zou, X., et al. 2002. Genes Dev. 16: 2923-34. PMID: 12435633
2. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.  |  Reddy, HK., et al. 2005. Cancer Res. 65: 10174-8. PMID: 16288002
3. Regulation of CDK4.  |  Bockstaele, L., et al. 2006. Cell Div. 1: 25. PMID: 17092340
4. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.  |  Colleoni, B., et al. 2017. Oncogene. 36: 4349-4361. PMID: 28368408
5. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.  |  Xu, G. and Li, JY. 2018. J Neurooncol. 136: 445-452. PMID: 29150788
6. Expression, purification and characterisation of a human anti-CDK4 single-chain variable fragment antibody.  |  Zhao, J., et al. 2021. BMC Biotechnol. 21: 71. PMID: 34930213
7. Sanguinarine promotes apoptosis of hepatocellular carcinoma cells via regulating the miR-497-5p/CDK4 axis.  |  Ding, Q., et al. 2022. Am J Transl Res. 14: 8539-8551. PMID: 36628219
8. Recent Progress in CDK4/6 Inhibitors and PROTACs.  |  Wang, H., et al. 2023. Molecules. 28: PMID: 38138549
9. Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma.  |  Shi, Y., et al. 2024. Biochem Biophys Res Commun. 708: 149808. PMID: 38520914
10. Hernandezine acts as a CDK4 suppressor inhibiting tumor growth by the CDK4/PKM2/NRF2 axis in colon cancer.  |  Lv, JL., et al. 2024. Phytomedicine. 131: 155775. PMID: 38838401

The preferred Cdk4 antibody is Cdk4 Antibody (DCS-35): sc-23896.